InMed Net Income from 2010 to 2026
| INM Stock | USD 0.88 0.01 1.12% |
Net Loss | First Reported 2001-09-30 | Previous Quarter -2.4 M | Current Value -1.7 M | Quarterly Volatility 1.3 M |
Check InMed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 289 K, Interest Expense of 352.6 K or Selling General Administrative of 7.9 M, as well as many indicators such as Price To Sales Ratio of 10.83, Dividend Yield of 0.0 or Days Sales Outstanding of 34.42. InMed financial statements analysis is a perfect complement when working with InMed Pharmaceuticals Valuation or Volatility modules.
InMed | Net Income | Build AI portfolio with InMed Stock |
Evaluating InMed Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into InMed Pharmaceuticals's fundamental strength.
Latest InMed Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of InMed Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in InMed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of InMed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is InMed Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InMed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.16 M) | 10 Years Trend |
|
Net Income |
| Timeline |
InMed Net Income Regression Statistics
| Arithmetic Mean | (6,435,865) | |
| Coefficient Of Variation | (74.22) | |
| Mean Deviation | 3,606,836 | |
| Median | (6,978,624) | |
| Standard Deviation | 4,776,577 | |
| Sample Variance | 22.8T | |
| Range | 18.6M | |
| R-Value | (0.63) | |
| Mean Square Error | 14.8T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (593,080) | |
| Total Sum of Squares | 365.1T |
InMed Net Income History
Other Fundumenentals of InMed Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
InMed Pharmaceuticals Net Income component correlations
About InMed Pharmaceuticals Financial Statements
InMed Pharmaceuticals investors utilize fundamental indicators, such as Net Income, to predict how InMed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.3 M | -7 M | |
| Net Loss | -7.3 M | -7.7 M | |
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | (372.20) | (390.81) | |
| Net Income Per E B T | 0.90 | 0.80 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of InMed Pharmaceuticals Correlation against competitors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.09) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.